AEON Biopharma, Inc. (AEON) News
Follow AEON Biopharma, Inc. (AEON) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
AEON Biopharma (AEON) Gets FDA Feedback Enabling Streamlined ABP-450 Path
AEON received FDA Type 2b meeting minutes indicating prior head-to-head ABP-450 vs BOTOX studies may be used as supportive evidence, and plans an IND in Q4 2026 for a CMAP PD study while deferring a comparative efficacy
REGULATION | Sep 30, 2026, 12:09 PM UTC
L
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging workAEON plans to submit an IND for CMAP pha
REGULATION | Sep 30, 2026, 12:09 PM UTC
L
AEON Biopharma receives FDA Type 2b minutes; plans IND for CMAP PD study, warrants to accelerate
AEON Biopharma received FDA Type 2b meeting minutes that support advancing ABP-450 toward a 351(k) BLA and plans to file an IND for a CMAP PD study in Q4 2026.Key Highlights:Original SEC Filing: AEON Biopharma, Inc. [ AE
REGULATION | Sep 30, 2026, 12:03 PM UTC
L
Fiscal Support Could Sustain Malaysia Consumer Spending — Market Talk
Malaysia's fiscal support could be doing the heavy lifting in sustaining consumer spending despite weaker sentiment, with private consumption growing 4.8% on year in 2Q, Hong Leong IB analyst Jonathan Ooi says in a note.
NEWS | Sep 29, 2026, 02:13 AM UTC
L
AEON pilot forced degradation results support ABP-450 comparability to BOTOX
AEON announced positive pilot forced degradation results supporting analytical comparability of ABP-450 to BOTOX.
EQUITY | Sep 09, 2026, 12:01 PM UTC
H
AEON Biopharma names Paul Lee acting chief regulatory officer
AEON Biopharma designates former FDA neuroscience leader Paul Lee, M.D., Ph.D. as acting chief regulatory officer.
REGULATION | Aug 24, 2026, 12:00 PM UTC
L
AEON reports expanded structural data for ABP-450
AEON says expanded structural data support molecular similarity of ABP-450 to BOTOX®; no magnitude, timing, or catalyst was supplied.
REGULATION | Aug 19, 2026, 12:00 PM UTC
L
AEON Biopharma Reports Q2 2026 Results
AEON Biopharma reports second quarter 2026 financial results and provides corporate update
EARNINGS | Aug 12, 2026, 08:15 PM UTC
M
AEON Regains NYSE Compliance
AEON meets NYSE American listing standards
EQUITY | Aug 03, 2026, 08:16 PM UTC
H
Why Aehr Test Systems Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of Aehr Test Systems (NASDAQ: AEHR ) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY27 sales guidance above estimates. Aehr Test Sy
MACRO | Jul 15, 2026, 08:32 AM UTC
L
Aeon announces pricing of upsized $13.75M public offering
Aeon announces pricing of upsized $13.75M public offering
EQUITY | Jul 14, 2026, 02:13 PM UTC